Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access |
Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc |
Journal website https://www.jofem.org |
Short Communication
Volume 11, Number 1, February 2021, pages 28-32
The Role of Inflammation in Contributing to Vascular Risk in Subclinical Hyperthyroidism: Randomized Controlled Trial
Figure
Table
Characteristics | Placebo (n = 18) | Carbimazole (n = 12) | P1 | P2 |
---|---|---|---|---|
All data except age and sex are expressed as median and range. P1 and P2 are the differences between placebo and carbimazole groups at visit 0 and visit 2, respectively. IHD: ischemic heart disease; BMI: body mass index; BP: blood pressure; TSH: thyroid stimulating hormone; FT4: free thyroxine; CRP: C-reactive protein; Lp-PLA2: lipoprotein associated phospholipase A2; NLR: neutrophil to lymphocyte ratio; MLR: monocyte to lymphocyte ratio. | ||||
Age (years) | 57 (46 - 63) | 55 (44 - 65.5) | 0.96 | - |
Sex M/F (%) | 5/13 (27.8/72.2) | 3/9 (25/75) | 0.99 | - |
Diabetes (%) | 6 (33.3) | 4 (33.3) | 0.99 | - |
Hypertension (%) | 8 (44.4) | 5 (41.7) | 0.99 | - |
Hyperlipidemia (%) | 6 (33.3) | 4 (33.3) | 0.99 | - |
IHD (%) | 1 (5.6) | 1 (8.3) | 0.99 | - |
Atrial fibrillation | 0 | 0 | - | - |
BMI (kg/m2) | 0.27 | 0.22 | ||
Visit 0 | 23.4 (21.1 - 26.3) | 25.0 (24.2 - 26.5) | ||
Visit 2 | 23.6 (21.6 - 26.6) | 25.2 (24.3 - 26.8) | ||
Systolic BP | 0.79 | 0.30 | ||
Visit 0 | 127.5 (119 - 140) | 128.5 (109.5 - 138.5) | ||
Visit 2 | 130.0 (116 - 146) | 124.5 (109.0 - 144.0) | ||
Diastolic BP | 0.64 | 0.34 | ||
Visit 0 | 71 (68 - 74) | 65.5 (63.5 - 82) | ||
Visit 2 | 70.5 (68 - 76) | 76.0 (68.5 - 82.0) | ||
FT4 (pmol/L) | 0.45 | 0.06 | ||
Visit 0 | 13 (12 - 15) | 13 (11.5 - 13.5) | ||
Visit 2 | 12.5 (11 - 14) | 11.5 (10.5 - 12.0) | ||
TSH (mIU/L) | 0.68 | 0.0008 | ||
Visit 0 | 0.19 (0.14 - 0.27) | 0.25 (0.1 - 0.29) | ||
Visit 2 | 0.33 (0.20 - 0.48) | 1.1 (0.7 - 2.3) | ||
CRP (mg/L) | 0.98 | 0.52 | ||
Visit 0 | 1.1 (0.20 - 16.8) | 1.5 (0.20 - 6.2) | ||
Visit 2 | 1.05 (0.2 - 11.3) | 1.1 ( 0.2 - 7.0) | ||
Lp-PLA2 (ng/mL) | 0.08 | 0.15 | ||
Visit 0 | 443.33 (55.98 - 7,129.43) | 191.16 (52.44 - 1,244.75) | ||
Visit 2 | 455.21 (68.87 - 3,904.35) | 207.79 (58.18 - 827.35) | ||
NLR | 0.28 | 0.87 | ||
Visit 0 | 1.69 (0.96 - 3.49) | 1.79 (1.10 - 5.21) | ||
Visit 2 | 2.10 (1.49 - 2.43) | 2.06 (1.59 - 2.52) | ||
MLR | 0.34 | 0.29 | ||
Visit 0 | 0.23 (0.12 - 0.41) | 0.26 (0.15 - 0.39) | ||
Visit 2 | 0.23 (0.20 - 0.28) | 0.23 (0.21 - 0.31) |